Skip to main content
. 2013 Apr 1;123(5):1976–1987. doi: 10.1172/JCI67388

Figure 5. The majority of TCD8 generated against naturally processed determinants confer protective immunity to VACV.

Figure 5

(A) Two vaccination schemes. Scheme I entailed priming with peptide formulated with anti-CD40 antibody and poly(I:C), while scheme II entailed priming with epitope-pulsed maturated DCs. (B–E) The top row of panels correspond to peptide vaccination using scheme I; the bottom row of panels correspond to vaccination using scheme II. (B) Epitope-specific TCD8 frequency determined with the indicated p/B7.2 tetramers in blood of vaccinated mice before VACV challenge. nd, not detected. (C) Lung VACV burdens in lethally infected mice evaluated on day 6 p.i. (D) Percentage of initial body weight for epitope-vaccinated mice weighed on day 6 after challenge. The dotted line indicates no recovery threshold (i.e., ~70% initial body weight). (E) Morbidity score for epitope-vaccinated mice evaluated on day 6 after challenge. Data are representative of 2 independent experiments. Each symbol represents 1 mouse (n = 5 per epitope). Horizontal bars indicate the mean. ***P < 0.001; **P < 0.01; *P < 0.05; ns, not significant as compared with mock in 1-way ANOVA with Dunnett’s post-hoc test. Mean ± SEM in D and E are shown.